Use of Aerosolized anti-TCR Monoclonal Antibodies as a Therapy for Airway Hyperresponsiveness
Monoclonal antibodies are specific and therefore various subsets of T cell population can be targeted.Low doses of antibody are required.The therapeutical effects of such technique are rapid.The delivery of these antibodies is confined to the airways and does not affect the peripheral immune system.
Therapy for asthma and chronic obstructive pulmonary disease
National Jewish Health scientists have demonstrated in a mouse model of asthma that targeted delivery of monoclonal antibodies anti-alpha beta or gamma delta T cells alleviate AHR: In addition, the same decrease in AHR was demonstrated in mice genetically-deficient in cells targeted by these antibodies. The same scientists have also shown that the cellular effects of these antibodies is localized exclusively to the airways and do not spread systemically.
Patent Number: US20020172677A1
Application Number: US2001826319A
Inventor: Lahn, Michael, F. | Born, Willi, K. | Kanehiro, Arihiko | Gelfand, Erwin
Priority Date: 3 Apr 2001
Priority Number: US20020172677A1
Application Date: 3 Apr 2001
Publication Date: 21 Nov 2002
IPC Current: A61K000900 | A61K0039395 | C07K001628
US Class: 4241451 | 424043
Title: Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
Usefulness: Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
Summary: The invention provides a method of reducing AHR in a mammal that has or is at risk of developing airway hyper-responsiveness. AHR associated with allergic inflammation can occur in a patient that has any chronic obstructive disease of the airways including asthma, chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic pneumonia, emphysema, bronchitis, allergic bronchitis bronchiectasis and cystic fibrosis.
诊断/治疗
其他疾病
美国
